UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Effects of DHA-rich n-3 fatty acid supplementation on gene expression in blood mononuclear leukocytes: the OmegAD study

PloS one, 2012-04, Vol.7 (4), p.e35425-e35425

2012

Volltextzugriff (PDF)

Effects of docosahexaenoic acid-rich n-3 fatty acid supplementation on cytokine release from blood mononuclear leukocytes: the OmegAD study

The American journal of clinical nutrition, 2008-06, Vol.87 (6), p.1616-1622

2008

Volltextzugriff (PDF)

Omega-3 supplementation in mild to moderate Alzheimer's disease: effects on neuropsychiatric symptoms

International journal of geriatric psychiatry, 2008-02, Vol.23 (2), p.161-169

2008

Volltextzugriff (PDF)

Cytokines and memory across the mature life span of women

Scandinavian journal of psychology, 2011-06, Vol.52 (3), p.229-235

2011

Volltextzugriff (PDF)

Docosahexaenoic acid stabilizes soluble amyloid‐β protofibrils and sustains amyloid‐β‐induced neurotoxicity in vitro

The FEBS journal, 2007-02, Vol.274 (4), p.990-1000

2007

Volltextzugriff (PDF)

Soluble interleukin-1 receptor type II, IL-18 and caspase-1 in mild cognitive impairment and severe Alzheimer's disease

Neurochemistry international, 2005-06, Vol.46 (7), p.551-557

2005

Volltextzugriff (PDF)

The cerebrocortical areas in normal brain aging and in alzheimer's disease: noticeable differences in the lipid peroxidation level and in antioxidant defense

Neurochemical research, 2001-04, Vol.26 (4), p.353-361

2001

Volltextzugriff (PDF)

Regional distribution of somatostatin receptor binding and modulation of adenylyl cyclase activity in Alzheimer's disease brain

Journal of the neurological sciences, 1991-10, Vol.105 (2), p.225-233

1991

Volltextzugriff (PDF)

Soluble interleukin-1 receptor type II levels are elevated in cerebrospinal fluid in Alzheimer's disease patients

Brain research, 1999-04, Vol.826 (1), p.112-116

1999

Volltextzugriff (PDF)

Effects of docosahexaenoic acid–rich n−3 fatty acid supplementation on cytokine release from blood mononuclear leukocytes: the OmegAD study1

The American journal of clinical nutrition, 2008-06, Vol.87 (6), p.1616-1622

2008

Volltextzugriff (PDF)

Omega-3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study: a randomized double-blind trial

Archives of neurology (Chicago), 2006-10, Vol.63 (10), p.1402

2006

Volltextzugriff (PDF)

Docosahexaenoic acid stabilizes soluble amyloid- beta protofibrils and sustains amyloid- beta -induced neurotoxicity invitro

The FEBS journal, 2007-02, Vol.274 (4), p.990-1000

2007

Volltextzugriff (PDF)

Docosahexaenoic acid stabilizes soluble amyloid-[beta] protofibrils and sustains amyloid-[beta]-induced neurotoxicity in vitro

The FEBS journal, 2007-02, Vol.274 (4), p.990

2007

Volltextzugriff (PDF)

O4-06-01: Docosahexaenoic acid stabilizes soluble amyloid-β protofibrils and sustains amyloid-β induced neurotoxicity In vitro

Alzheimer's & dementia, 2006-07, Vol.2 (3), p.S87-S87

2006

Volltextzugriff (PDF)

P2-130: Correlation of inflammatory factors with Alzheimer biomarkers

Alzheimer's & dementia, 2006-07, Vol.2 (3), p.S271-S272

2006

Volltextzugriff (PDF)

P3-453: Weight gain by Omega-3 fatty acids in patients with Alzheimer’s disease

Alzheimer's & dementia, 2006-07, Vol.2 (3), p.S509-S509

2006

Volltextzugriff (PDF)

O3-05-08: A randomized double-blind trial with omega-3 fatty acid treatment in mild to moderate Alzheimer’s disease

Alzheimer's & dementia, 2006-07, Vol.2 (3), p.S64-S64

2006

Volltextzugriff (PDF)

Calcium ion transients in neutrophils from patients with sporadic Alzheimer's disease

Neuroscience letters, 1998-10, Vol.255 (2), p.95-98

1998

Volltextzugriff (PDF)

White matter lesions and soluble interleukin-1 receptor type II in CSF from demented and non-demented subjects

Neurochemistry international, 2002-10, Vol.41 (4), p.217-222

2002

Volltextzugriff (PDF)

Värt ge symtomlindrande läkemedel vid Alzheimers sjukdom [Administration of symptom-relieving drugs in Alzheimer disease is beneficial]

Läkartidningen, 2006, Vol.103 (6), p.369

2006

Volltextzugriff (PDF)

Diminished [ 3H]inositol(1,4,5)P 3 but not [ 3H]inositol(1,3,4,5)P 4 binding in Alzheimer's disease brain

Brain research, 1995, Vol.681 (1), p.160-166

1995

Volltextzugriff (PDF)

Diminished [3H]inositol(1,4,5)P3 but not [3H]inositol(1,3,4,5)P4 binding in Alzheimer's disease brain

Brain research, 1995-05, Vol.681 (1-2), p.160-166

1995

Volltextzugriff (PDF)

Administration of symptom-relieving drugs in Alzheimer disease is beneficial

Läkartidningen, 2006-02, Vol.103 (6), p.369-371

2006

Volltextzugriff (PDF)

Disturbances in signal transduction mechanisms in Alzheimer's disease

Molecular and cellular biochemistry, 1995-08, Vol.149-150 (1), p.287-292

1995

Volltextzugriff (PDF)

Receptor‐Effector Coupling Dysfunctions in Alzheimer's Diseasea

Annals of the New York Academy of Sciences, 1996-06, Vol.786 (1), p.294-304

1996

Volltextzugriff (PDF)

1 – 25 von 35

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(33)
Mit Volltextzugriff
(33)

Publikationsform

Artikel
(35)

Sprache

Englisch
(33)
Schwedisch
(2)

Erscheinungsjahr

n.n

Thema

Humans
(20)
Science & Technology
(20)
Life Sciences & Biomedicine
(19)
Medicin Och Hälsovetenskap
(16)
Biological And Medical Sciences
(14)
Alzheimer's Disease
(13)
Aged
(12)
Female
(12)
Neurosciences
(12)
Neurosciences & Neurology
(12)
Male
(11)
Medical Sciences
(9)
Neurology
(9)
Alzheimer Disease - Physiopathology
(7)
Fundamental And Applied Biological Sciences. Psychology
(7)
Middle Aged
(7)
Aged, 80 And Over
(6)
Alzheimer Disease - Metabolism
(6)
Biochemistry & Molecular Biology
(6)
Signal Transduction
(6)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Effects of DHA-rich n-3 fatty acid supplementation on gene expression in blood mononuclear leukocytes: the OmegAD study

Effects of docosahexaenoic acid-rich n-3 fatty acid supplementation on cytokine release from blood mononuclear leukocytes: the OmegAD study

Omega-3 supplementation in mild to moderate Alzheimer's disease: effects on neuropsychiatric symptoms

Cytokines and memory across the mature life span of women

Docosahexaenoic acid stabilizes soluble amyloid‐β protofibrils and sustains amyloid‐β‐induced neurotoxicity in vitro

Soluble interleukin-1 receptor type II, IL-18 and caspase-1 in mild cognitive impairment and severe Alzheimer's disease

The cerebrocortical areas in normal brain aging and in alzheimer's disease: noticeable differences in the lipid peroxidation level and in antioxidant defense

Regional distribution of somatostatin receptor binding and modulation of adenylyl cyclase activity in Alzheimer's disease brain

Soluble interleukin-1 receptor type II levels are elevated in cerebrospinal fluid in Alzheimer's disease patients

Effects of docosahexaenoic acid–rich n−3 fatty acid supplementation on cytokine release from blood mononuclear leukocytes: the OmegAD study1

Omega-3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study: a randomized double-blind trial

Docosahexaenoic acid stabilizes soluble amyloid- beta protofibrils and sustains amyloid- beta -induced neurotoxicity invitro

Docosahexaenoic acid stabilizes soluble amyloid-[beta] protofibrils and sustains amyloid-[beta]-induced neurotoxicity in vitro

O4-06-01: Docosahexaenoic acid stabilizes soluble amyloid-β protofibrils and sustains amyloid-β induced neurotoxicity In vitro

P2-130: Correlation of inflammatory factors with Alzheimer biomarkers

P3-453: Weight gain by Omega-3 fatty acids in patients with Alzheimer’s disease

O3-05-08: A randomized double-blind trial with omega-3 fatty acid treatment in mild to moderate Alzheimer’s disease

Calcium ion transients in neutrophils from patients with sporadic Alzheimer's disease

White matter lesions and soluble interleukin-1 receptor type II in CSF from demented and non-demented subjects

Värt ge symtomlindrande läkemedel vid Alzheimers sjukdom [Administration of symptom-relieving drugs in Alzheimer disease is beneficial]

Diminished [ 3H]inositol(1,4,5)P 3 but not [ 3H]inositol(1,3,4,5)P 4 binding in Alzheimer's disease brain

Diminished [3H]inositol(1,4,5)P3 but not [3H]inositol(1,3,4,5)P4 binding in Alzheimer's disease brain

Administration of symptom-relieving drugs in Alzheimer disease is beneficial

Disturbances in signal transduction mechanisms in Alzheimer's disease

Receptor‐Effector Coupling Dysfunctions in Alzheimer's Diseasea

Suchergebnisse filtern